Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quantum computing applications in drug discovery.

Briefings in bioinformatics·2026

Same author

A Multistage Virtual Screening Strategy Integrating Molecular Similarity, Deep Learning Scoring, and Molecular Docking toward the Discovery of Novel LRRK2 Inhibitors.

Journal of chemical information and modeling·2026

Same author

SMPD1-mediated sphingolipid metabolism dysregulation in predicting and preventing in-stent restenosis of coronary heart disease patients.

Journal of pharmaceutical analysis·2026

Same author

Integrated computational and experimental approaches for drug repurposing targeting key Mycobacterium tuberculosis proteins.

Molecular diversity·2026

Same author

Integrated multi-omics reveals population-specific mechanisms of cardiovascular disease in high-altitude environments.

iScience·2026

Same author

Enhancing ADMET property predictions using cross-aligned multimodal attention mechanisms.

Molecular diversity·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Protocol for using scCURE to construct an immunotherapy outcome prediction model.

Yujun Liu¹, Xin Zou², Henry H Y Tong³

¹Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

|December 11, 2024

Summary

This summary is machine-generated.

Predicting cancer immunotherapy success is difficult. This study introduces scCURE, a method using single-cell RNA sequencing (scRNA-seq) to identify key cells, enabling better prediction of treatment outcomes.

Keywords:

Bioinformatics Cancer Health Sciences

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jun 12, 2025

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

An R-Based Landscape Validation of a Competing Risk Model

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Area of Science:

Computational Biology
Immunology
Genomics

Background:

Predicting patient response to cancer immunotherapy remains a significant clinical challenge.
Baseline patient status is insufficient for accurate immunotherapy outcome prediction.
Novel computational methods are needed to analyze complex biological data for predictive modeling.

Purpose of the Study:

To introduce a novel protocol, scCURE (single-cell RNA sequencing-based changed and unchanged cell recognition during immunotherapy), for predicting immunotherapy outcomes.
To detail the methodology for identifying unchanged cells from scRNA-seq data using scCURE.
To demonstrate the construction of prediction models using scCURE-identified cells from both scRNA-seq and bulk RNA sequencing (RNA-seq) data.

Main Methods:

Utilized single-cell RNA sequencing (scRNA-seq) data to identify cells with stable functions during immunotherapy.
Developed the scCURE algorithm to discriminate between changed and unchanged cells based on cellular and molecular profiles.
Constructed predictive models for immunotherapy outcomes leveraging the identified unchanged cells from scRNA-seq and bulk RNA-seq datasets.

Main Results:

Successfully demonstrated a protocol for recognizing unchanged cells crucial for immunotherapy response.
Established a framework for building immunotherapy prediction models based on scCURE-identified cell populations.
Showcased the applicability of the scCURE method for both scRNA-seq and bulk RNA-seq data analysis.

Conclusions:

The scCURE protocol provides a robust method for identifying key cellular populations that can improve immunotherapy outcome prediction.
This approach offers a valuable tool for enhancing personalized cancer treatment strategies.
Further research and validation of scCURE are warranted for broader clinical application.